The incidence of thyroid cancer is increasing yearly in the United States. Although the overall prognosis from thyroid cancer is excellent, no effective therapies exist for patients with distant metastases. The presence of capsular or vascular invasion is the most important predictor of outcome from thyroid cancer. Over the past decade, the oncogenes responsible for approximately 50% of thyroid cancers have been characterized, and all appear to cause constitutive activation of the PI3 kinase/Akt and MAP kinase pathways. We have demonstrated that levels of activated Akt (pAkt), in particular, are enhanced in the majority of thyroid cancers in the cells invading through tumor capsules or metastatic to cervical lymph nodes, and that the degree and localization of pAkt correlates with oncogene expression. Of particular interest is that the enhancement of pAkt occurs in the nucleus of the invading cells, pAkt co-localizes with the Aktl isoform, and nuclear pAkt is associated with cytosolic p27. Because of this unique association with nuclear Akt activity in thyroid cancer invasion in vivo, we questioned whether Akt activation in the nucleus might play an important role in inducing invasion in thyroid tumor cancer. Subsequent in vitro studies have demonstrated that thyroid cancer cell motility is associated with nuclear pAkt and cytosolic p27, and is dependent on Aktl and p27 expression. In an effort to define a regulatory mechanism for subcellular localization of Aktl, we identified the presence of a conserved functioning CRM-1 binding nuclear export signal (NES) in Akt 1. Mutation of the Aktl/NES disrupts CRM-1 binding and results in nuclear accumulation of Aktl with associated nuclear Akt activity. Expression of a nuclear export-deficient Aktl in Aktl-/- murine embryonic fibroblasts restores cell motility without inducing growth, in a p27 dependent manner. These data suggest that nuclear Aktl activity plays a functional role in cell motility. We now hypothesize that nuclear Aktl activity is a critical regulator of thyroid cancer cell motility and that regulation of Akt nuclear/cytoplasmic shuttling by thyroid oncogenes may be an important pathway for aggressive thyroid cancer behavior.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA102572-05
Application #
7616474
Study Section
Integrative and Clinical Endocrinology and Reproduction Study Section (ICER)
Program Officer
Snyderwine, Elizabeth G
Project Start
2005-07-06
Project End
2011-04-30
Budget Start
2009-05-01
Budget End
2011-04-30
Support Year
5
Fiscal Year
2009
Total Cost
$251,966
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Saji, M; Narahara, K; McCarty, S K et al. (2011) Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene 30:4307-15
Paes, John E; Hua, Keding; Nagy, Rebecca et al. (2010) The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. J Clin Endocrinol Metab 95:4244-50
Saji, Motoyasu; Ringel, Matthew D (2010) The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 321:20-8
Espinosa, Allan V; Shinohara, Motoo; Porchia, Leonardo M et al. (2009) Regulator of calcineurin 1 modulates cancer cell migration in vitro. Clin Exp Metastasis 26:517-26
Nadella, Kiran S; Saji, Motoyasu; Jacob, Naduparambil K et al. (2009) Regulation of actin function by protein kinase A-mediated phosphorylation of Limk1. EMBO Rep 10:599-605
Ringel, Matthew D (2009) Molecular markers of aggressiveness of thyroid cancer. Curr Opin Endocrinol Diabetes Obes 16:361-6
Ringel, Matthew D (2008) ""Thyroid cancer"" cell line misidentification: a time for proactive change. J Clin Endocrinol Metab 93:4226-7
Paes, John E; Ringel, Matthew D (2008) Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am 37:375-87, viii-ix
Porchia, Leonardo M; Guerra, Marcy; Wang, Yu-Chieh et al. (2007) 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Mol Pharmacol 72:1124-31
Espinosa, A V; Porchia, L; Ringel, M D (2007) Targeting BRAF in thyroid cancer. Br J Cancer 96:16-20

Showing the most recent 10 out of 12 publications